Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

British Medical Journal

- PMLiVE

Almirall celebrates new offices in China to advance innovation in dermatology

The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners

- PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Around 64 million people worldwide live with psoriasis

- PMLiVE

Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

- PMLiVE

Almirall and Absci expand AI dermatological drug discovery partnership

The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in difficult-to-treat plaque psoriasis

An estimated eight million people in the US are living with the immune-mediated skin disease

- PMLiVE

Almirall hosts Skin Academy to advance skin science and dermatology treatments

The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

- PMLiVE

Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis

Plaque psoriasis affects up to 90% of patients with the immune-mediated disease

- PMLiVE

J&J and Protagonist share promising phase 3 results for icotrokinra in plaque psoriasis

More than 125 million people globally are estimated to be living with the skin disorder

- PMLiVE

Dermavant reports positive long-term results for Vtama cream in atopic dermatitis

More than 26 million people in the US are affected by the inflammatory skin condition

- PMLiVE

Johnson & Johnson’s Tremfya shows promise in ‘special site’ plaque psoriasis

The immune-mediated disease affects more than 125 million people worldwide

- PMLiVE

Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis

At least 100 million people worldwide are affected by the immune-mediated disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links